• <center id="my6c6"></center>
    <rt id="my6c6"><acronym id="my6c6"></acronym></rt>
  • <abbr id="my6c6"></abbr>
  •  

    上海強世信息科技有限公司

    Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
    作者:Yoshihara K1, Gao Y, Shiga H, Wada DR, Hisaoka M. | 發布:Yuting Yang | 發布時間: 2018-09-10 | 1251 次瀏覽 | 分享到:
    Abstract

    BACKGROUND:
    Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype.

    OBJECTIVE:
    To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertensive patients, and to evaluate effects of covariates on the apparent oral clearance (CL/F), with particular emphasis on the effect of race.

    DESIGN:
    Retrospective analysis of data from 12 phase I-III trials in the US, Europe and Japan.

    PARTICIPANTS:
    Eighty-nine healthy volunteers and 383 hypertensive patients.

    METHODS:
    Nonlinear mixed-effects modelling was used to evaluate 7911 olmesartan plasma sample concentrations. The covariates included age, bodyweight, sex, race (Westerners [including Caucasians and Hispanics] versus Japanese), patient status (hypertensive patients versus healthy volunteers), serum creatinine level as an index of renal function and serum chemistry data as indices of hepatic function.

    RESULTS:
    The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6.66 L/h for a typical male Western hypertensive patient), absorption rate constant (1.46h-1), elimination rate constant (0.193h-1), rate constant from the central to peripheral compartment (0.061h-1), rate constant from the peripheral to central compartment (0.079h-1) and absorption lag-time (0.427h). Analysis of covariates showed that age, bodyweight, sex, patient status and renal function were factors influencing the clearance of olmesartan.

    CONCLUSION:
    The population pharmacokinetic analysis of olmesartan showed that: (i) severe renal impairment (serum creatinine >265 micromol/L [approximately 3 mg/dL]) could cause a clearance decrease of > or =30%; (ii) older age, lower bodyweight and being female were determinants of lower clearance but their effects on olmesartan clearance were within 20%; (iii) no statistically significant difference in clearance was found between Westerners and Japanese.
    久久精品国1国二国三| 国产精自产拍久久久久久| 9久久免费国产精品特黄| 性刺激久久久久久久久| 久久免费区一区二区三波多野| 国产精品免费久久久久影院| 2021精品国产综合久久| 香蕉久久一区二区不卡无毒影院 | 成人综合伊人五月婷久久| 一本狠狠久久五月色丁香| 国产精品久久新婚兰兰| 久久亚洲精品AB无码播放| 99久久免费国产精品热| 九九久久精品国产AV片国产| 久久亚洲精品高潮综合色a片| ...91久久精品一区二区三区| 久久夜色精品国产亚洲AV动态图| 综合久久一区二区三区 | 久久精品国产亚洲av麻| 久久久久99精品成人片牛牛影视| 青草久久精品亚洲综合专区| 伊人情人综合成人久久网小说| 久久久精品人妻一区二区三区蜜桃| 久久九九国产精品怡红院| 久久综合久久精品| 久久综合九色综合97_久久久 | 国产精品久久久久久网站| 伊人久久大香线蕉无码| 国产精品揄拍一区二区久久| 亚洲国产精品综合久久2007| 久久天天躁狠狠躁夜夜avapp| 久久久久琪琪去精品色无码| 久久老子午夜精品无码| 久久综合九色综合97免费下载| 久久99国产精品久久| 精品午夜久久福利大片| 久久亚洲精品视频| 亚洲成色www久久网站夜月| 久久精品国产清白在天天线| 国产V亚洲V天堂无码久久久| 久久精品国产成人|